E7070: A novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer

Anti-Cancer Drugs

Volumn 13, Issue 10, 2002, Pages 989-997

  Van Kesteren, Charlotte ^a   Beijnen, Jos H ^a,b   Schellens, Jan H M ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cell cycle inhibitor; E7010; E7070; Sulfonamide

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; CYCLIN E; FLUOROURACIL; INDISULAM; IRINOTECAN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PACLITAXEL; SULFONAMIDE; UNCLASSIFIED DRUG;

ALOPECIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CLINICAL TRIAL; COLON CANCER; CONJUNCTIVITIS; DIARRHEA; DOSE RESPONSE; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; FOLLICULITIS; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SOLID TUMOR; STOMATITIS; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; G1 PHASE; HUMANS; NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036866878     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200211000-00002     Document Type: Review

References (33)

1. 1 phase: A promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001; 8: 1487-503.
2. Sherr JC. Cancer cell cycles. Science 1993; 274: 1672-7.
3. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35: 1886-94.
4. Sauer K, Lehner CF. The role of cyclin E in the regulation of entry into the S phase. Prog Cell Cycle Res 1995; 1: 125-39.
5. Yoshino H, Ueda N, Niijma J, et al. Novel sulfonamides as potential, systemically active antitumor agents. J Med Chem 1992; 35: 2496-7.
6. Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol 1976; 16: 309-27.
7. Yoshimatsu K, Yamaguchi A, Yoshino N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997; 57: 3208-13.
8. Nihei Y, Suzuki M, Okano A, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999; 90: 1387-95.
9. Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijio N. Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cells. Jpn J Cancer Res 1998; 89: 954-62.
10. Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994; 54: 1702-6.
11. Yamamoto K, Noda K, Yoshimura A, et al. Phase I study of E7010. Cancer Chemother Pharmacol 1998; 42: 127-34.
12. Funahashi Y, Koyanagi N, Kitoh K. Effect of E7010 in liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor. Cancer Chemother Pharmacol 2001; 47: 179-84.
13. Owa T, Okauchi T, Yoshimatsu K, et al. A focused compound library of novel N-(7-indolyl)-benzene-sulfonamides for the discovery of potent cell cycle inhibitors. Bioorg Med Chem Lett 2000; 10: 1223-6.
14. 1 phase of the cell cycle. J Med Chem 1999; 42: 3789-99.
15. 1 phase. III. Studies of mechanism of action. Proc Am Ass Cancer Res 1996; 37: 391.
16. Fukuoka K, Usuda J, Fukumoto H, et al. Mechanism of action of a novel sulfonamide antitumor agent, E7070. Proc Am Ass Cancer Res 2000; 41: 59.
17. Ozawa Y, Sugi NH, Nagasu T, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 2001; 37: 2275-82.
18. Ozawa Y, Sugi NH, Nagasu T, et al. Corrigendum to 'E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo'. Eur J Cancer 2002; 38: 736.
19. Tsukahara K, Watanabe T, Hata-Sugi N, Yoshimatsu K, Okayama H, Ngasu T. Anticancer agent E7070 inhibits amino acid and uracil transport in fission yeast. Mol Pharmacol 2001; 60: 1254-9.
20. Ozawa Y, Kai J, Kusano K, Asada M, Yoshimatsu K. Synergistic effect of E7070 combined with CPT-11 in human tumor xenograft models. Proc NCI-EORTC-AACR 2000; 11: 144.
21. Raymond E, ten Bokkel Huinink WW, Taïeb J, et al. Phase I and pharmacokinetic study of E7070, a novel chloro-indolysulfonamide cell cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 2002; in press.
22. Punt CJA, Fumoleau P, van de Walle B, et al. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily × 5 schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG). Ann Oncol 2001; 12: 1289-93.
23. Droz JP, Roch H, Zanetta S, et al. Phase I trial of five-days continuous infusion E7070. [N(3-chloro-7-indoly)-1,4-bezene-disulfonamide] in patients with solid tumors. Proc Am Ass Cancer Res 2000; 41: 609.
24. Dittrich C, Dumez H, Calvert H, et al. Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single IV infusion, weekly × 4, q 6 weeks. Proc Am Ass Cancer Res 2000; 41: 609.
25. Raymond E, Fumoleau P, Roché H, et al. Combined results of 4 phase I and pharmacokinetic studies of E7070, a novel chloroindoly-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clin Cancer Res 2000; 6: 4529s.
26. Van Kesteren Ch, Mathôt RAA, Raymond E, et al. Population pharmacokinetics of the novel anti-cancer agent E7070 during four phase I studies: Model building and validation. J Clin Oncol 2002; in press.
27. van Kesteren Ch, Mathôt RAA, Raymond E, et al. Population pharmacokinetics and pharmacokinetic - Pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies. Br J Clin Pharmacol 2002; 53: 553P.
28. Van den Bongard HJGD, Pluim D, Rosing H, et al. An excretion balance and pharmacokinetic study of the anticancer agent E7070 in cancer patients. Anti-Cancer Drugs 2002; 13: 807-14.
29. Mainwaring PN, van Cutsem E, van Laethem JL, et al. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Proc Am Ass Cancer Res 2002; 21: 153a.
30. Talbot D, Norbury C, Slade M, et al. A phase II and pharmacodynamic study of E7070 in patients with non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy. Proc Am Ass Cancer Res 2002; 21: 327a.
31. Owa T, Yokoi A, Kuromitsu J, et al. Microarray-based expression profiling of sulfonamide antitumor agents. Proc Am Ass Cancer Res 2001; 42: 371.
32. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 2001; 19: 265-72.
33. Eisenhauer EA. Phase I and II trials of novel anticancer agents: Endpoints, efficacy and existentialism. Ann Oncol 1998; 9: 1047-52.